Repository logo

Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios.

Published version



Change log


Harris, Ross J 
Thomas, Brenda 
Griffiths, Jade 
Costella, Annastella 
Chapman, Ruth 


BACKGROUND & AIMS: Hepatitis C (HCV) related disease in England is predicted to rise, and it is unclear whether treatment at current levels will be able to avert this. The aim of this study was to estimate the number of people with chronic HCV infection in England that are treated and assess the impact and costs of increasing treatment uptake. METHODS: Numbers treated were estimated using national data sources for pegylated interferon supplied, dispensed, or purchased from 2006 to 2011. A back-calculation approach was used to project disease burden over the next 30 years and determine outcomes under various scenarios of treatment uptake. RESULTS: 5000 patients were estimated to have been treated in 2011 and 28,000 in total from 2006 to 2011; approximately 3.1% and 17% respectively of estimated chronic infections. Without treatment, incident cases of decompensated cirrhosis and hepatocellular carcinoma were predicted to increase until 2035 and reach 2290 cases per year. Treatment at current levels should reduce incidence by 600 cases per year, with a peak around 2030. Large increases in treatment are needed to halt the rise; and with more effective treatment the best case scenario predicts incidence of around 500 cases in 2030, although treatment uptake must still be increased considerably to achieve this. CONCLUSIONS: If the infected population is left untreated, the number of patients with severe HCV-related disease will continue to increase and represent a substantial future burden on healthcare resources. This can be mitigated by increasing treatment uptake, which will have the greatest impact if implemented quickly.



Back-calculation, Disease burden, Hepatitis C, Liver disease, Modelling, Treatment, Adult, Antiviral Agents, Carcinoma, Hepatocellular, Cost of Illness, End Stage Liver Disease, England, Health Care Costs, Hepatitis C, Chronic, Humans, Interferon-alpha, Liver Cirrhosis, Liver Neoplasms, Middle Aged, Models, Statistical, Polyethylene Glycols, Recombinant Proteins, Retrospective Studies, Ribavirin, Risk Factors, Treatment Outcome

Journal Title

J Hepatol

Conference Name

Journal ISSN


Volume Title



Elsevier BV